Associate Professor Richard Haynes
|Tel||+44 (0)1865 743607|
- MRC Project Leader Track
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he now works on randomized trials and epidemiology (particularly in renal medicine and cardiovascular disease) at CTSU.
Biliary Tract and Liver Complications in Polycystic Kidney Disease.
Judge PK. et al, (2017), J Am Soc Nephrol, 28, 2738 - 2748
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.
Schlackow I. et al, (2017), Heart
Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.
Reith C. et al, (2017), BMC Nephrol, 18
Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).
Staplin N. et al, (2017), Clin J Am Soc Nephrol, 12, 546 - 552
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
Herrington W. et al, (2017), Hypertension, 69, 314 - 322